Home / Health / Thyroid Recall Hits Highest Danger Level
Thyroid Recall Hits Highest Danger Level
24 Sep
Summary
- Thyroid medicine recall escalated to Class I, its highest risk.
- Superpotent 30mg thyroid tablets pose serious health risks.
- Consumers should consult doctors before stopping medication.
The U.S. Food and Drug Administration has classified a thyroid medicine recall as a Class I, its most severe risk category. This recall affects one lot of Vitruvias Therapeutics' 30 mg thyroid tablets, identified by specific NDC and lot numbers. The issue stems from the potential for these tablets to be superpotent, containing a higher concentration of the active ingredient than prescribed.
This elevated risk level indicates that the use of these superpotent thyroid tablets is likely to cause serious adverse health effects or even death. Symptoms of consuming superpotent thyroid medication can include an overactive thyroid, leading to issues such as weight loss, heat intolerance, fatigue, and hypertension. Vitruvias Therapeutics had not reported any adverse events related to this recall as of August 24, 2025.
Individuals currently using the recalled thyroid tablets are urged not to discontinue their medication abruptly. Instead, they should seek immediate guidance from their healthcare provider. Consumers with questions or concerns can reach out to Vitruvias Therapeutics directly via email or phone for further information and assistance.
